Working to Eradicate Gynecologic Cancers

448 - Poster Session B
CA-125 as a response marker for vintafolide+pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer: the PRECEDENT trial

Sunday, March 23, 2014: 7:00 PM
West Exhibit Hall (Tampa Convention Center)
R. W. Naumann1, M. Bidzinski2, C. Lovejoy3, K. Anderson4, R. Rangwala5 and E. Kutarska6
1Carolinas Medical Center, Charlotte, NC, 2Holycross Cancer Center, Kielce, Poland, 3Endocyte, Inc., West Lafayette, IN, 4Merck & Co., Inc., Whitehouse Station, NJ, 5Merck Research Laboratories, North Wales, PA, 6Centrum Onkologii Ziemi Lubelskiej, Lublin, Poland
 
See more of: Poster Session B
See more of: Poster Session
<< Previous Presentation | Next Presentation >>